Investors are taking notice as Hemostemix Inc's stock jumps significantly in today's trading session.
Hemostemix Inc (HEM.V) is experiencing a remarkable surge in its stock price, rising by 7.69% today. This uptick comes amidst a backdrop of recent corporate activities that may be fueling investor enthusiasm.
Advertisement
Hemostemix Inc
HEM.V
HEM.V
Hemostemix Inc
WealthAwesomeAdvertisement
Market cap
$14.35M
52W high
$0.14
52W low
$0.04
1W change
+0.00%
Beta
0.61
Analyst Price Targets
Based on analyst covering HEM
Wall Street analysts forecast HEM stock price to rise 1376.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.96
+1376.9% Upside
Current Price
C$0.07
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HEM's historical volatility
30-Day Vol
137.6%
Annualized
90-Day Vol
116.1%
Annualized
Trend (90d)
-31.1%
Annualized drift
90d Mean
C$0.06
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.06 | C$0.04 – C$0.10 |
| 60 trading days | C$0.06 | C$0.03 – C$0.12 |
| 90 trading days | C$0.06 | C$0.03 – C$0.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: With a market cap of approximately CA$14.35 million, Hemostemix's recent private placements could be positioning the company for future growth, making it a stock to watch for investors looking for potential opportunities in the biotech sector.
Hemostemix Inc's stock rises 7.69% today
The stock is currently priced at CA$0.07, reflecting a growing interest in the company's future potential.
Bull case
The recent successful private placements have provided Hemostemix with important capital to advance its clinical and commercialization initiatives, especially regarding its ACP-01 therapy. This financial support could improve the company's prospects and attract more investment.
Bear case
Despite the positive movement in stock price, Hemostemix has not yet shown profitability, with a profit margin of 0%. Investors should stay cautious as the company navigates its growth path in a competitive biotech landscape.
Advertisement
Recent Corporate Developments
Hemostemix Inc recently closed a second tranche of its private placement, raising CA$322,250 by issuing 6,445,000 units. This funding is crucial for the company's ongoing projects and could be a key factor in the stock's positive performance today. For more details, check out our Hemostemix Inc stock page.
Market Sentiment and Future Outlook
The market's reaction to Hemostemix's recent fundraising efforts suggests a growing confidence in the company's strategy. As they work toward advancing their ACP-01 therapy, investors are keenly observing how these developments will impact future operations. Stay updated on Hemostemix's journey by visiting our stock analysis.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
